


BARDEX® I.C.® Anti-Infective Foley Catheters

with Bacti-Guard®* Silver Alloy Coating and Bard® Hydrogel

Make clinical decisions based on high levels of evidence

Over the past several years, clinically significant advances in urological infection control have contributed to a reduced incidence of catheter-associated urinary tract infections (CAUTIs).^{1,2,3} Bard has been at the forefront of these advances with the Bardex® I.C. Anti-Infective Foley Catheter, which has been documented extensively in the literature, and has been studied in multiple clinical trials.⁴



Only the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating has the highest level of evidence supporting its infection control properties.

The Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating is engineered for trusted performance without compromising patient safety.

The Bardex® I.C. Anti-Infective Foley Catheters with Bacti-Guard®* silver alloy coating have been clinically proven to provide protection from CAUTIs.

A Public Health Action Plan to Combat Antimicrobial Resistance. Published by the CDC, FDA, NIH, et al. January 2001. [Summary, Overview, Section II – Prevention and Control Action Items]

Adams A, Currie BP, Mullaney K. Reduction of nosocomial urinary tract infections with the Bardex I.C. Foley system [abstract]. Presented at Society for Healthcare Epidemiology of America (SHEA), 2002.

Ahearn DG, Grace DT, Jennings MJ, Borazjani RN, Boles KJ, Rose LJ, Simmons RB, Ahanotu EN. Effects of hydrogel/silver coatings on *in vitro* adherence to catheters of bacteria associated with urinary tract infections. *Current Microbiology*. 2000; 41:120-125.

Borazjani R, Ahearn AD. Reduced *in vitro* adherence to biomaterials of vancomycin-resistant versus vancomycin-sensitive enterococci [abstract]. Presented at Society for Healthcare Epidemiology of America (SHEA), 1998.

Evidence Report/Technology Assessment: Making health care safer: A critical analysis of patient safety practices. Agency for Healthcare Research and Quality. July 2001. [Contents, Summary, and Chapter 15 – Prevention of Nosocomial Urinary Tract Infections]

Gabriel MM, Sawant AD, Simmons RB, Ahearn DG. Effects of silver on adherence of bacteria to urinary catheters: *in vitro* studies. *Current Microbiology*. 1995; 30:17-22.

Gerberding JL. Hospital-onset infections: a patient safety issue. *Annals of Internal Medicine*. 2002; 137:665-670.

Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. *Archives of Internal Medicine*. 2000; 160:3294-3298.

Lai KK, Fontecchio S. Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. *American Journal of Infection Control*. 2002; 30:221-225.

Leape LL, Berwick DM, Bates DW. What practices will most improve patient safety? Evidence-based medicine meets patient safety. *JAMA*. 2002; 288:501-507.

Lettau LA, Blackhurst DW. Silver hydrogel-coated urinary catheters for the prevention of nosocomial urinary tract infections (NUTI): a collaborative study in 9 community hospitals [abstract]. *Clinical Infectious Disease*. 1998; 27:1020. Presented at Infectious Disease Society of America (IDSA), 1998.

Liedberg H. Catheter induced urethral inflammatory reaction and urinary tract infection. An experimental and clinical study. *Scandinavian Journal of Urology & Nephrology-Supplement*. 1989; 124:1-43.

Liedberg H, Lundberg T. Silver alloy coated catheters reduce catheter-associated bacteriuria. *British Journal of Urology*. 1990; 65:379-381.

Liedberg H, Lundberg T, Ekman P. Refinements in the coating of urethral catheters reduces the incidence of catheter-associated bacteriuria. *European Urology*. 1990; 17:236-240.

Lundberg T. Prevention of catheter-associated urinary-tract infections by use of silver-impregnated catheters [letter]. *Lancet*. 1986; 2:1031.

Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. *Emerging Infectious Diseases*. 2001; 7:342-347.

Newton T, Still JM, Law E. A comparison of the effect of early insertion of standard latex and silver-impregnated latex Foley catheters on urinary tract infections in burn patients. *Infection Control and Hospital Epidemiology*. 2002; 23:217-218.

Peninger M, Rex JH, Tidemann T, Brothers J, Brown G, Marciniak D, et al. Cost-benefit of a silver alloy, hydrogel-coated latex urinary catheter (SCCATH) in a large healthcare system [abstract]. Presented at Association for Professionals in Infection Control and Epidemiology (APIC), 2001.

Plowman R, Graves N, Esquivel J, Roberts JA. An economic model to assess the cost and benefits of the routine use of silver alloy coated urinary catheters to reduce the risk of urinary tract infections in catheterized patients. *Journal of Hospital Infection*. 2001; 48:33-42.

Ramirez R, Dobin A, Britten E, Wadman S. A silver opportunity for reducing nosocomial urinary tract infection [abstract]. Presented at Society for Healthcare Epidemiology of America (SHEA), 1998.

Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. *Archives of Internal Medicine*. 2000; 160:2670-2675.

Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. *American Journal of Medicine*. 1998; 105:236-241.

Salgado CD, Karchmer TB, Farr BM. Prevention of catheter-associated urinary tract infections. In: Wenzel RP, ed. *Prevention and Control of Nosocomial Infections*. 4th ed. Philadelphia: Lippincott Williams & Wilkins. 2003; 297-311.

Thomas L, Valainis G, Johnson J. A multi-site, cohort-matched trial of an anti-infective urinary catheter [abstract]. Presented at Society for Healthcare Epidemiology of America (SHEA), 2002.

Tu LM, Polanski MA, Framow HD, Gordon DA, Whitmore KE. Hydrogel/silver ion coated urinary catheter reduces the nosocomial urinary infection rates in intensive care units [abstract]. Presented at American Urological Association (AUA), 1998.

Verleyen P, De Ridder D, Van Poppel H, Baert L. Clinical application of the Bardex IC Foley catheter. *European Urology*. 1999; 36:240-246.

References

1. Maki DG, Tambyah PA. Engineering out the risk of infection with urinary catheters. *Emer Infect Dis*. 2001;7:342-347.
2. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM. A randomized crossover study of silver-coated urinary catheters in hospitalized patients. *Arch Int Med*. 2000;160:3294-3298.
3. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. *Arch Int Med*. 2000;160:2670-2675.
4. Data on file. Bard Medical Division.

www.bardmedical.com

Bard Medical Division
C.R. Bard, Inc.
8195 Industrial Blvd.
Covington, GA 30014
800-526-4455



Please consult product label and insert for any indications, contraindications, hazards, warnings, cautions and directions for use.
The Foley catheters included in the Bardex® I.C. System contain Bacti-Guard® silver alloy coating, which is licensed from Bactiguard AB.
Bard, Bardex, and the I.C. logo are registered trademarks of C.R. Bard, Inc., or an affiliate.
Bacti-Guard is a registered trademark of Bactiguard AB.
©2006 C.R. Bard, Inc. All Rights Reserved. 0309-08 R11/06 PBW P12/06


**Evidence-Based
Medicine**

Demand high levels of evidence to support clinical decisions

The levels of clinical evidence

Demand evidence from the highest levels to ensure the most appropriate clinical decisions are made.

Higher levels of evidence



Lower levels of evidence

Evidence in support of the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating and Bard® Hydrogel

Rupp, et al. *Am J Infec Control*. 2004
 Maki, et al. *Emer Infect Dis*. 2001.
 Karchmer, et al. *Arch Inter Med*. 2000.
 Verleyen, et al. *Eur Urol*. 1999.
 Liedberg, et al. *Eur Urol*. 1990.
 Liedberg and Lundeberg. *Br J Urol*. 1990.
 Lundeberg. *Lancet*. 1986.

Wenzel, ed. *Prevention and Control of Nosocomial Infections*. 4th ed. 2003.
 Leape, et al. *JAMA*. 2002.
 AHRQ Evidence Report. *Making Health Care Safer: A Critical Analysis of Patient Safety Practices*. 2001.

Saint, et al. *Am J Med*. 1998.

Newton, et al. *Infec Control Hosp Epi*. 2002.
 Lai, et al. *Am J Infec Control*. 2002.

Gerberding. *Ann Intern Med*. 2002.

Plowman, et al. *J Hosp Infec*. 2001.
 Saint, et al. *Arch Inter Med*. 2000.

Thomas, et al. SHEA, 2002.
 Adams, et al. SHEA, 2002.
 Lettau and Blackhurst. IDSA, 1998.

Mueller, et al. APIC, 2002.
 Peninger, et al. APIC, 2001.
 Tu, et al. AUA, 1998.
 Ramirez, et al. SHEA, 1998.

Over 20 abstracts presented at scientific conferences

Ahearn, et al. *Curr Microbiol*. 2000.
 Gabriel, et al. *Curr Microbiol*. 1995.

Liedberg. *Scand J Urol Nephrol Suppl*. 1989.

Jennings, et al. ICAAC, 2000.
 Borazjani and Ahearn. SHEA, 1998.

The practice of Evidence-Based Medicine is dependent on the use of the best available high level evidence.

Only the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating and Bard® Hydrogel is supported by the highest level of clinical evidence.